IEEE Pulse Highlights Bob Wynalek and DiscGenics

Bob Wynalek, as COO of DiscGenics, is highlighted in an article for his work on developing IDCT, an injectable disc cell therapy aimed at treating degenerative disc disease. The therapy combines differentiated progenitor cells, known as discogenic cells, with a proprietary scaffold carrier, focusing on restoring function and reducing pain by rebuilding the extracellular matrix within the disc. DiscGenics' approach is notable for its potential long-lasting effects and is currently preparing for a phase III clinical trial, with hopes of IDCT reaching the market by 2027.

For the full text and more details, please visit the IEEE Pulse article.